Aug. 1, 2022
Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.